Alumis Inc. · NASDAQ:ALMS

Alumis — Technical Presentation (March 2024)

16 slides from Alumis's technical presentation, March 2024

  1. Slide 1: Efficacy and Safety of ESK-001, a Highly Selective Oral TYK2 Inhibitor, in a Phase 2 Study

    Efficacy and Safety of ESK-001, a Highly Selective Oral TYK2 Inhibitor, in a Phase 2 Study (STRIDE) and OLE Study in Adults with Moderate-to-Severe Plaque Psoriasis Kim A. Papp1, Howard Sofen2, Roman G. Rubio3, Nicholas E. Vlahakis3, Sibel Ucpinar3, Grace Ma3, Regan Burns3, Elena Hitraya3 and Andrew

  2. Slide 2: Disclosure of Relationships with Industry

    Disclosure of Relationships with Industry Kim Papp, MD, PhD, FRCPC, FAAD S026: Late Breaking Research: Session 1 〉 AbbVie: Advisory Board, Consultant, Investigator, Speaker 〉 Dermira: Advisory Board, Investigator 〉 Novartis: Consultant, Investigator, Speaker 〉 Acelyrin: Consultant, Investigator 〉 Do

  3. Slide 3: ESK-001: A Selective Oral Allosteric TYK2i Achieves Maximal TYK2 Inhibition for 24 hours

    ESK-001: A Selective Oral Allosteric TYK2i Achieves Maximal TYK2 Inhibition for 24 hours at 40 mg BID dose ESK-001 Inhibition of Type 1 IFN Gene Signature* ESK-001 Allosteric binding TYK2 Kinase active JH2 domain JH1 domain ESK-001, a highly selective allosteric TYK2 inhibitor 〉High intrinsic TYK2 s

  4. Slide 4: ESK-001 Phase 2 STRIDE and OLE Studies Designed to Assess Short- and Long-Term Efficacy

    ESK-001 Phase 2 STRIDE and OLE Studies Designed to Assess both Short- and Long-Term Efficacy STRIDE Phase 2 Trial (N=228) Open Label Extension Trial (N=165) Double Blind Period Treatment ESK-001 10 mg QD (N=36) Withdrawal / Safety follow up ESK-001 20 mg QD (N=36) period ESK-001 40 mg QD (N=82) ESK-

  5. Slide 5: STRIDE: Demographics and Baseline Disease Characteristics Well-Balanced Across Study Arms

    STRIDE: Demographics and Baseline Disease Characteristics were Well-Balanced Across Study Arms Placebo 10 mg QD 20 mg QD 20 mg BID 40 mg QD 40 mg BID Overall (N=38) (N=36) (N=36) (N=40) (N=39) (N=39) (N=228) Age, mean (SD) 49.1 (11.7) 48.8 (12.7) 43.9 (12.0) 47.7 (12.5) 49.5 (10.5) 47.9 (14.2) 47.8

  6. Slide 6: STRIDE Safety at Week 16

    STRIDE Safety at Week 16 Placebo 10 mg QD 20 mg QD 20 mg BID 40 mg QD 40 mg BID Overall (N=38) (N=36) (N=36) (N=39) (N=39) (N=39) (N=227) Subjects with ≥1 TEAE 15 ( 39.5) 19 ( 52.8) 14 ( 38.9) 18 ( 46.2) 19 ( 48.7) 25 ( 64.1) 110 ( 48.5) Subjects with ≥1 SAE 0 1 (2.8) 0 3 ( 7.7) 1 (2.6) 0 5 ( 2.2) S

  7. Slide 7: Primary and Secondary PASI Endpoints Achieved at Week 16 with Dose-Dependent Efficacy

    STRIDE: Primary and Secondary PASI Endpoints Achieved at Week 12 with Dose-Dependent Increase in Efficacy PASI 75 PASI 90 PASI 100 Primary Endpoint 100 90 Proportion of Patients with *** 80 *** *** 70 64.1 Response (%) 60 56.4 56.4 *** *** 50 *** *** 38.5 40 ** 33.3 * 30 * 25.6 25.6 * 19.4 20 15.4 0

  8. Slide 8: Secondary sPGA Endpoints Achieved at Week 16 with Increasing Efficacy Over Time

    STRIDE: Secondary sPGA Endpoints Achieved at Week 12 with Increasing Efficacy Observed over Time sPGA 0/1 sPGA 0 100% 100% Proportion of Patients with Response (%) Proportion of Patients with Response (%) 80% 80% *** *** 59.0% 60% 60% 50.0% 40% 40% ** * 23.1% 17.9% * 20% 8.1% 20% 11.1% 5.1% 0% 2.7%

  9. Slide 9: 94% of Eligible STRIDE Subjects Continued in OLE Study

    94% of Eligible STRIDE Subjects Continued in OLE Study Open Label Extension Trial 228 204 165* ESK-001 40 mg QD (N=82) Randomized Subjects Eligible Phase 2 STRIDE Completing Subjects ESK-001 40 mg BID (N=82) Subjects STRIDE Entering OLE 8 31 Eligible for OLE Ineligible and but chose not not particip

  10. Slide 10: OLE: Safety Summary

    OLE: Safety Summary ESK-001 40 mg QD ESK-001 40 mg BID Overall (N=82) (N=82) (N=164) Subjects with ≥ 1 TEAE 35 ( 42.7) 38 ( 46.3) 73 ( 44.5) Subjects with ≥ 1 SAE1 1 ( 1.2) 1 ( 1.2) 2 ( 1.2) Deaths 0 0 0 Subjects with TEAE leading 0 2 ( 2.4) 2 ( 1.2) to treatment discontinuation2 Subjects with TEAE

  11. Slide 11: OLE Efficacy: Continued ESK-001 Exposure Achieves Significant Increases in PASI Responses

    STRIDE and OLE Efficacy: Continued ESK-001 Exposure Achieves Significant Increases in PASI Responses OLE Treatment: ESK-001 40 mg BID 100 STRIDE Washout 20 mg BID 40 mg QD 80 40 mg BID Placebo Patient with Response (%) 60 53.7 46.3 40 24.4 23.2 20 11.0 0.0 6.1 0 VISIT > Baseline Parent Wk 12 Day 1 W

  12. Slide 12: OLE Efficacy: Continued ESK-001 Exposure Achieves Significant Increases in PASI Responses

    STRIDE and OLE Efficacy: Continued ESK-001 Exposure Achieves Significant Increases in PASI Responses OLE Treatment: ESK-001 40 mg BID 100 90.9 STRIDE Washout Open Label Extension 89.2 90.3 PASI 75 20 mg BID 40 mg BID 40 mg QD 80 40 mg BID Placebo Patient with Response (%) 60 53.7 46.3 40 24.4 23.2 2

  13. Slide 13: OLE Efficacy: Continued ESK-001 Exposure Achieves Significant Increases in PASI Responses

    STRIDE and OLE Efficacy: Continued ESK-001 Exposure Achieves Significant Increases in PASI Responses OLE Treatment: ESK-001 40 mg BID 100 90.9 STRIDE Washout Open Label Extension 89.2 90.3 PASI 75 20 mg BID 40 mg BID 40 mg QD 80 40 mg BID 72.7 Placebo PASI 90 Patient with Response (%) 60 53.7 58.1 5

  14. Slide 14: OLE Efficacy: Continued ESK-001 Exposure Achieves Significant Increases in PASI Responses

    STRIDE and OLE Efficacy: Continued ESK-001 Exposure Achieves Significant Increases in PASI Responses OLE Treatment: ESK-001 40 mg BID 100 90.9 STRIDE Washout Open Label Extension 89.2 90.3 PASI 75 20 mg BID 40 mg BID 40 mg QD 80 40 mg BID 72.7 Placebo PASI 90 Patient with Response (%) 60 53.7 58.1 5

  15. Slide 15: OLE Efficacy: Continued ESK-001 Exposure Achieves Significant Increases in PASI Responses

    STRIDE and OLE Efficacy: Continued ESK-001 Exposure Achieves Significant Increases in PASI Responses OLE Treatment: ESK-001 40 mg BID 100 90.9 STRIDE Washout Open Label Extension 89.2 90.3 PASI 75 20 mg BID 40 mg BID 40 mg QD 80 40 mg BID 72.7 Placebo 80.5 80.2 PASI 90 Patient with Response (%) 60 5

  16. Slide 16: Conclusions

    Conclusions STRIDE and OLE studies demonstrate ESK-001 is a clinically effective and generally safe oral therapy and support continued Phase 3 development of ESK-001 in plaque psoriasis Efficacy Summary 〉Clear dose dependent efficacy demonstrated in STRIDE and OLE studies – Maximal TYK2 inhibition a

Alumis — Technical Presentation (March 2024) on 6ix